Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc

<< Previous

Bullboard Posts

Next >>

Post by TechOneon Dec 16, 2024 1:39pm

108 Views

Post# 36364548

Spectral on Linkedin Today

Toraymyxin™ (PMX) is a blood purification therapy designed to enhance the clearance of endotoxins in patients with severe sepsis and endotoxemia. It is a hemoperfusion cartridge that uses polymyxin B, an antibiotic immobilized on a fiber matrix, to bind and remove endotoxins (toxic components of Gram-negative bacteria) directly from the bloodstream.

Mechanism: Blood is passed through the cartridge, where polymyxin B binds to endotoxins, neutralizing their effects and helping to reduce inflammation and improve organ function.

Indications: Used for patients with endotoxemia and septic shock, particularly when caused by Gram-negative bacteria.

Global Use: Toraymyxin has been approved and used in Europe and Japan since the 1990s & 2000s respectively and has been used safely on more than 340,000 patients worldwide.

Clinical Impact: Studies have shown that Toraymyxin can improve hemodynamic stability, reduce vasopressor requirements, and potentially enhance survival rates in critically ill patients.

Toraymyxin™ is currently undergoing a Phase 3 clinical trial and is not approved for clinical use in the USA.

<< Previous

Bullboard Posts

Next >>

Invest wiser with BMO's InvestorLine Platform features